Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection

doi:10.3748/wjg.v20.i32.11415

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 32

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7567)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

510

WORD

213

HTML

4109

Figures (1-1)

221

Tables (1-3)

200

Sum=5253

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1169

Download

1145

Sum=2314

Aug 28, 2014 (publication date) through Dec 29, 2024

Times Cited of This Article

Times Cited (33)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Clinical Trial

World J Gastroenterol. Aug 28, 2014; 20(32): 11415-11421
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11415

Table 2 Eradication of Helicobacter pylori infection in the different treatment groups in the intention-to-treat and per protocol analyses n (%)

Efficacy	Group 1 (n = 180)	Group 2 (n = 180)	Group 3 (n = 180)	Group 4 (n = 180)	χ²	P value
Eradication success	134 (74.4)	149 (82.8)	142 (78.9)	155 (86.1)
Eradication failure	31 (17.2)	18 (10.0)	24 (13.3)	13 (7.2)
Cases dropped	15 (8.3)	13 (7.2)	14 (7.8)	12 (6.7)
Eradication rate
ITT (95%CI)	74.4% (68.0-80.8)	82.8% (77.3-88.3)	78.9% (72.9-84.9)	86.1%^a (81.0-91.2)	8.725	0.033
PP (95%CI)	81.2% (75.2-87.2)	89.2% (84.5-93.9)	85.5% (80.1-90.9)	92.3%^a (88.3-96.3)	10.094	0.018

^aP < 0.05 vs Group 1. Patients in Group 1 and Group 3 received rabeprazole (10 mg), amoxicillin (1000 mg) and furazolidone (100 mg) twice daily for 7 and 10 d, respectively and patients in Group 2 and Group 4 received rabeprazole (10 mg), bismuth (220 mg), amoxicillin (1000 mg) and furazolidone (100 mg) twice daily for 7 and 10 d, respectively. ITT: Intention-to-treat; PP: Per protocol.

Citation: Xie Y, Zhu Y, Zhou H, Lu ZF, Yang Z, Shu X, Guo XB, Fan HZ, Tang JH, Zeng XP, Wen JB, Li XQ, He XX, Ma JH, Liu DS, Huang CB, Xu NJ, Wang NR, Lu NH. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection. World J Gastroenterol 2014; 20(32): 11415-11421
URL: https://www.wjgnet.com/1007-9327/full/v20/i32/11415.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i32.11415